

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
3 June 2004 (03.06.2004)

PCT

(10) International Publication Number
WO 2004/046139 A1

(51) International Patent Classification⁷: **C07D 413/12**,
419/12, 413/14, 419/14, 307/80, A61P 3/04, 3/08

John, Wall [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(21) International Application Number:
PCT/GB2003/004919

(74) Agent: **ASTRAZENECA**; Global Intellectual Property,
P O Box 272, Mereside, Alderley Park, Macclesfield,
Cheshire SK10 4GR (GB).

(22) International Filing Date:
13 November 2003 (13.11.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0226930.6 19 November 2002 (19.11.2002) GB

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except MG, US*): **ASTRAZENECA AB** [SE/SE]; Sodertalje, S-151 85 (SE).

(71) Applicant (*for MG only*): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

Published:

— with international search report


(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MCKERRECHER, Darren** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **RAYNER,**

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/046139 A1

(54) Title: **BENZOFURAN DERIVATES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF**



(I)

(57) Abstract: Compound of formula (I) wherein A is selected from pyridin-2-yl or thiazol-2-yl and R¹, R² and R³ are as described in the specification and their use in the treatment or prevention of a disease or medical conditions mediated through glucokinase.

BENZOFURAN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF

The present invention relates to chemical compounds useful in the treatment or prevention of a disease or medical conditions mediated through glucokinase (GLK), leading
5 to a decreased glucose threshold for insulin secretion. In addition the compounds are predicted to lower blood glucose by increasing hepatic glucose uptake. Such compounds may have utility in the treatment of type 2 diabetes and obesity. The invention also relates to processes for preparing said compounds, pharmaceutical compositions comprising said compounds, and the use of such a compound in the conditions described above.

10 In the pancreatic β -cell and liver parenchymal cells the main plasma membrane glucose transporter is GLUT2. Under physiological glucose concentrations the rate at which GLUT2 transports glucose across the membrane is not rate limiting to the overall rate of glucose uptake in these cells. The rate of glucose uptake is limited by the rate of phosphorylation of glucose to glucose-6-phosphate (G-6-P) which is catalysed by glucokinase
15 (GLK) [1]. GLK has a high (6-10mM) K_m for glucose and is not inhibited by physiological concentrations of G-6-P [1]. GLK expression is limited to a few tissues and cell types, most notably pancreatic β -cells and liver cells (hepatocytes) [1]. In these cells GLK activity is rate limiting for glucose utilisation and therefore regulates the extent of glucose induced insulin secretion and hepatic glycogen synthesis. These processes are critical in the maintenance of
20 whole body glucose homeostasis and both are dysfunctional in diabetes [2].

In one sub-type of diabetes, type 2 maturity-onset diabetes of the young (MODY-2), the diabetes is caused by GLK loss of function mutations [3, 4]. Hyperglycaemia in MODY-2 patients results from defective glucose utilisation in both the pancreas and liver [5]. Defective glucose utilisation in the pancreas of MODY-2 patients results in a raised threshold for
25 glucose stimulated insulin secretion. Conversely, rare activating mutations of GLK reduce this threshold resulting in familial hyperinsulinism [6, 7]. In addition to the reduced GLK activity observed in MODY-2 diabetics, hepatic glucokinase activity is also decreased in type 2 diabetics [8]. Importantly, global or liver selective overexpression of GLK prevents or reverses the development of the diabetic phenotype in both dietary and genetic models of the
30 disease [9-12]. Moreover, acute treatment of type 2 diabetics with fructose improves glucose tolerance through stimulation of hepatic glucose utilisation [13]. This effect is believed to be mediated through a fructose induced increase in cytosolic GLK activity in the hepatocyte by the mechanism described below [13].

- 2 -

Hepatic GLK activity is inhibited through association with GLK regulatory protein (GLKRP). The GLK/GLKRP complex is stabilised by fructose-6-phosphate (F6P) binding to the GLKRP and destabilised by displacement of this sugar phosphate by fructose-1-phosphate (F1P). F1P is generated by fructokinase mediated phosphorylation of dietary fructose.

5 Consequently, GLK/GLKRP complex integrity and hepatic GLK activity is regulated in a nutritionally dependent manner as F6P is elevated in the post-absorptive state whereas F1P predominates in the post-prandial state. In contrast to the hepatocyte, the pancreatic β -cell expresses GLK in the absence of GLKRP. Therefore, β -cell GLK activity is regulated exclusively by the availability of its substrate, glucose. Small molecules may activate GLK
10 either directly or through destabilising the GLK/GLKRP complex. The former class of compounds are predicted to stimulate glucose utilisation in both the liver and the pancreas whereas the latter are predicted to act exclusively in the liver. However, compounds with either profile are predicted to be of therapeutic benefit in treating type 2 diabetes as this disease is characterised by defective glucose utilisation in both tissues.

15 GLK and GLKRP and the K_{ATP} channel are expressed in neurones of the hypothalamus, a region of the brain that is important in the regulation of energy balance and the control of food intake [14-18]. These neurones have been shown to express orectic and anorectic neuropeptides [15, 19, 20] and have been assumed to be the glucose-sensing neurones within the hypothalamus that are either inhibited or excited by changes in ambient
20 glucose concentrations [17, 19, 21, 22]. The ability of these neurones to sense changes in glucose levels is defective in a variety of genetic and experimentally induced models of obesity [23-28]. Intracerebroventricular (icv) infusion of glucose analogues, that are competitive inhibitors of glucokinase, stimulate food intake in lean rats [29, 30]. In contrast, icv infusion of glucose suppresses feeding [31]. Thus, small molecule activators of GLK may
25 decrease food intake and weight gain through central effects on GLK. Therefore, GLK activators may be of therapeutic use in treating eating disorders, including obesity, in addition to diabetes. The hypothalamic effects will be additive or synergistic to the effects of the same compounds acting in the liver and/or pancreas in normalising glucose homeostasis, for the treatment of Type 2 diabetes. Thus the GLK/GLKRP system can be described as a potential
30 "diabesity" target (of benefit in both Diabetes and Obesity).


In WO 00/58293 and WO 01/44216 (Roche), a series of benzylcarbamoyl compounds are described as glucokinase activators. The mechanism by which such compounds activate GLK is assessed by measuring the direct effect of such compounds in an assay in which GLK

- 3 -

activity is linked to NADH production, which in turn is measured optically - see details of the *in vitro* assay described below. Compounds of the present invention may activate GLK directly or may activate GLK by inhibiting the interaction of GLKRP with GLK. Many compounds of the present invention may show favourable selectivity compared to known GLK activators.

International application number: WO03/000267 describes a group of benzoyl amino pyridyl carboxylic acids which are activators of the enzyme glucokinase (GLK), International application number WO03/015774 describes a group of benzoylamino heterocycle compounds as glucokinase activators and International application number WO03/000262 describes a group or vinyl phenyl derivatives as glucokinase activators.

According to the present invention there is provided a compound of formula (I):



(I)

wherein:

Ring A is pyridin-2-yl or thiazol-2-yl; wherein said pyridin-2-yl or thiazol-2-yl may be optionally substituted on carbon by one or more groups selected from R^4 ;

One of R^1 and R^2 is hydrogen and the other is hydrogen or C_{1-4} alkyl; wherein R^1 and R^2 may be substituted on carbon by one or more groups selected from R^5 ;

R^3 is selected from C_{1-4} alkyl, C_{1-4} alkoxy, carbocyclyl, heterocyclyl, carbocycloxy and heterocycloxy; wherein R^3 may be independently optionally substituted on carbon by one or more groups selected from R^6 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by C_{1-4} alkyl;

R^4 is selected from halo, carboxy and C_{1-4} alkyl;

R^5 and R^6 are independently selected from halo, C_{1-4} alkyl, C_{1-4} alkoxy, N -(C_{1-4} alkyl)amino, N,N -(C_{1-4} alkyl)₂amino, carbocyclyl, heterocyclyl, carbocycloxy, heterocycloxy and carbocyclidenyl; wherein R^5 and R^6 may be independently optionally substituted on carbon by one or more R^7 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by C_{1-4} alkyl;

- 4 -

R^7 is selected from halo, carboxy, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and *N*-methyl-*N*-ethylamino; or a salt, solvate or pro-drug thereof.

Compounds of formula (I) may form salts which are within the ambit of the invention.

- 5 Pharmaceutically acceptable salts are preferred although other salts may be useful in, for example, isolating or purifying compounds.

The term "halo" includes chloro, bromo, fluoro and iodo; preferably chloro, bromo and fluoro; most preferably fluoro.

- In this specification the term "alkyl" includes both straight and branched chain alkyl groups. For example, " C_{1-4} alkyl" and " C_{1-6} alkyl" includes propyl, isopropyl and *t*-butyl.

- A "carbocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a $-CH_2-$ group can optionally be replaced by a $-C(O)-$. Preferably "carbocyclyl" is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for "carbocyclyl" include cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl. Particularly "carbocyclyl" is cyclohexyl or phenyl. Most particularly phenyl.

- A "heterocyclyl" is a saturated, partially saturated or unsaturated, monocyclic or bicyclic ring containing 3-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, wherein a $-CH_2-$ group can optionally be replaced by a $-C(O)-$ or sulphur atoms in a heterocyclic ring may be oxidised to $S(O)$ or $S(O)_2$. A "heterocyclyl" ring may, unless otherwise specified, be carbon or nitrogen linked, unless linking via nitrogen leads to a quaternary nitrogen. Preferably a "heterocyclyl" is a saturated, partially saturated or unsaturated, monocyclic or bicyclic ring wherein each ring contains 5 or 6 atoms of which 1 to 3 atoms are nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a $-CH_2-$ group can optionally be replaced by a $-C(O)-$ or sulphur atoms in a heterocyclic ring may be oxidised to $S(O)$ or $S(O)_2$ groups. More preferably a "heterocyclyl" is a saturated, partially saturated or unsaturated, monocyclic ring wherein each ring contains 5 or 6 atoms of which 1 to 3 atoms are nitrogen, sulphur or oxygen. Further preferably a "heterocyclyl" is a partially saturated or unsaturated monocyclic ring wherein each ring contains 5 or 6 atoms, preferably 5 atoms, of which 1 to 2 atoms are nitrogen, sulphur or oxygen.

- Examples and suitable values of the term "heterocyclyl" are thiazolidinyl, pyrrolidinyl, pyrrolinyl, 2-pyrrolidonyl, 2,5-dioxopyrrolidinyl, 2-benzoxazolinonyl, 1,1-dioxotetrahydrothienyl, 2,4-dioxoimidazolidinyl, 2-oxo-1,3,4-(4-triazolinyl), 2-oxazolidinonyl, 5,6-dihydrouracilyl, 1,3-benzodioxolyl, 1,2,4-oxadiazolyl, 2-azabicyclo[2.2.1]heptyl, 4-thiazolidonyl, morpholino, 2-oxotetrahydrofuranlyl, tetrahydrofuranlyl, 2,3-dihydrobenzofuranlyl, benzothienyl, isoxazolyl, tetrahydropyranlyl, piperidyl, 1-oxo-1,3-dihydroisoindolyl, piperazinyl, thiomorpholino, 1,1-dioxothiomorpholino, tetrahydropyranlyl, 1,3-dioxolanyl, homopiperazinyl, thienyl, isoxazolyl, imidazolyl, pyrrolyl, thiazolyl, thiadiazolyl, isothiazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, pyranlyl, indolyl, pyrimidyl, thiazolyl, pyrazinyl, pyridazinyl, pyridyl, 4-pyridonyl, quinolyl and 1-isoquinolonyl. Preferably the term "heterocyclyl" refers to monocyclic heterocyclic rings with 5- or 6-membered systems, such as isoxazolyl, pyrrolidinyl, 2-pyrrolidonyl, 2,5-dioxopyrrolidinyl, morpholino, tetrahydrofuranlyl, piperidyl, piperazinyl, thiomorpholino, tetrahydropyranlyl, thienyl, imidazolyl, 1,2,4-triazolyl, 1,3,4-triazolyl, indolyl, thiazolyl, thiadiazolyl, pyrazinyl, pyridazinyl and pyridyl. Preferred examples of 5/6 and 6/6 bicyclic ring systems include benzofuranlyl, benzimidazolyl, benzthiophenyl, benzthiazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, pyridoimidazolyl, pyrimidoimidazolyl, quinolinylyl, isoquinolinylyl, quinoxalinylyl, quinazolinylyl, phthalazinyl, cinnolinylyl and naphthyridinylyl.
- Examples of C₁₋₄alkyl and C₁₋₆alkyl include methyl, ethyl, propyl, isopropyl, *sec*-butyl and *tert*-butyl; examples of C₁₋₄alkoxy include methoxy, ethoxy, propoxy and *tert*-butoxy; examples of *N*-(C₁₋₄alkyl)amino include methylamino, ethylamino and isopropylamino; examples of *N,N*-(C₁₋₄alkyl)₂amino include dimethylamino, *N*-methyl-*N*-ethylamino and *N*-ethyl-*N*-isopropylamino; examples of carbocyclylidenyl are cyclopentylidenyl and 2,4-cyclohexadien-1-ylidenyl.

- It is to be understood that, insofar as certain of the compounds of formula (I) defined below may exist in optically active or racemic forms by virtue of one or more asymmetric carbon atoms, the invention includes in its definition any such optically active or racemic form which possesses the property of stimulating GLK directly or inhibiting the GLK/GLKRP interaction. The synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form. It is also to be understood that certain compounds may exist in tautomeric forms and that the invention also

- 6 -

relates to any and all tautomeric forms of the compounds of the invention which activate GLK.

Suitable compounds of formula (I) are those wherein any one or more of the following apply. Such values may be used where appropriate with any of the definitions, claims or
5 embodiments defined hereinbefore or hereinafter.

Ring A is pyridin-2-yl optionally substituted on carbon by one or more groups selected from R⁴.

Ring A is thiazol-2-yl optionally substituted on carbon by one or more groups selected from R⁴.

10 Ring A is pyridin-2-yl or thiazol-2-yl; wherein said pyridin-2-yl or thiazol-2-yl may be optionally substituted on carbon by one or more groups selected from R⁴ wherein: R⁴ is carboxy.

Ring A is unsubstituted or is substituted by carboxy.

Ring A is pyridin-2-yl, 5-carboxypyridin-2-yl, thiazol-2-yl or 5-carboxythiazol-2-yl.

15 Ring A is 5-carboxypyridin-2-yl, thiazol-2-yl or 5-carboxythiazol-2-yl.

R¹ is hydrogen and R² is C₁₋₄alkyl; wherein R² may be substituted on carbon by one or more groups selected from R⁵.

R¹ is C₁₋₄alkyl and R² is hydrogen; wherein R¹ may be substituted on carbon by one or more groups selected from R⁵.

20 One of R¹ and R² is hydrogen and the other is hydrogen or C₁₋₄alkyl.

R¹ is hydrogen or C₁₋₄alkyl and R² is hydrogen.

Both R¹ and R² are hydrogen.

R¹ is methyl or hydrogen and R² is hydrogen.

R³ is selected from C₁₋₄alkoxy and carbocycloxy; wherein R³ may be independently
25 optionally substituted on carbon by one or more groups selected from R⁶;

wherein: R⁶ is selected from halo, carbocyclyl, heterocyclyl, carbocyclidenyl; wherein R⁶ may be optionally substituted on carbon by one or more R⁷; wherein:

R⁷ is selected from halo and methyl.

R³ is selected from C₁₋₄alkoxy; wherein R³ may be independently optionally
30 substituted on carbon by one or more groups selected from R⁶;

wherein: R⁶ is selected from carbocyclyl and heterocyclyl; wherein R⁶ may be optionally substituted on carbon by one or more R⁷; wherein:

R⁷ is selected from halo and methyl.

- 7 -

R³ is selected from methoxy, ethoxy, *iso*-butoxy, phenoxy and benzocyclopent-1-yloxy; wherein R³ may be independently optionally substituted on carbon by one or more groups selected from R⁶;

wherein: R⁶ is selected from fluoro, phenyl, isoxazolyl, thienyl and cyclopentylidenyl;

5 wherein R⁶ may be optionally substituted on carbon by one or more R⁷; wherein:

R⁷ is selected from fluoro and methyl.

R³ is selected from methoxy, ethoxy and *iso*-butoxy; wherein R³ may be independently optionally substituted on carbon by one or more groups selected from R⁶; wherein: R⁶ is selected from phenyl, isoxazolyl and thienyl; wherein R⁶ may be optionally

10 substituted on carbon by one or more R⁷; wherein:

R⁷ is selected from fluoro and methyl.

R³ is selected from 2-fluorobenzoyloxy, 5-methylisoxazol-3-ylmethoxy, 2-thien-3-ylethoxy, cyclopentylidenylmethoxy, 1-cyclopentylidenylethoxy, phenoxy, benzocyclopent-1-yloxy and 2-phenyl-2,2-difluoroethoxy.

15 R³ is selected from 2-fluorobenzoyloxy, 5-methylisoxazol-3-ylmethoxy and 2-thien-3-ylethoxy.

Therefore in a further aspect of the invention, there is provided a compound of formula (I) (as depicted above) wherein

20 Ring A is pyridin-2-yl or thiazol-2-yl; wherein said pyridin-2-yl or thiazol-2-yl may be optionally substituted on carbon by one or more groups selected from R⁴ wherein:

R⁴ is carboxy;

R¹ is methyl or hydrogen and R² is hydrogen; and

R³ is selected from C₁₋₄alkoxy; wherein R³ may be independently optionally substituted on carbon by one or more groups selected from R⁶; wherein:

25 R⁶ is selected from carbocyclyl and heterocyclyl; preferably phenyl, thienyl or isoxazolyl, wherein R⁶ may be optionally substituted on carbon by one or more R⁷; wherein:

R⁷ is selected from halo and methyl;

or a salt, solvate or pro-drug thereof.

30 Therefore in a further aspect of the invention, there is provided a compound of formula (I) (as depicted above) wherein

Ring A is 5-carboxypyridin-2-yl, thiazol-2-yl or 5-carboxythiazol-2-yl;

R¹ is methyl or hydrogen and R² is hydrogen; and

- 8 -

R³ is selected from 2-fluorobenzyloxy, 5-methylisoxazol-3-ylmethoxy and 2-thien-3-ylethoxy;

or a salt, solvate or pro-drug thereof.

In another aspect of the invention, preferred compounds of the invention include:

- 5 2-methyl-4-isobutoxy-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;
 2-methyl-4-(2-fluorophenylmethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;
 2-methyl-4-isobutoxy-6-[N-(5-carboxythiazol-2-yl)carbamoyl]benzofuran;
 2-methyl-4-(5-methylisoxazol-3-ylmethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;
10 4-(2-fluorophenylmethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;
 4-(5-methylisoxazol-3-ylmethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;
 2-methyl-4-(thien-2-ylethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran; and
 2-methyl-4-isobutoxy-6-[N-(thiazol-2-yl)carbamoyl]benzofuran
15 or a salt, solvate or pro-drug thereof.

The compounds of the invention may be administered in the form of a pro-drug. A pro-drug is a bioprecursor or pharmaceutically acceptable compound being degradable in the body to produce a compound of the invention (such as an ester or amide of a compound of the invention, particularly an *in vivo* hydrolysable ester). Various forms of prodrugs are known in
20 the art. For examples of such prodrug derivatives, see:

- a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, *et al.* (Academic Press, 1985);
b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen;
c) H. Bundgaard, Chapter 5 "Design and Application of Prodrugs", by H. Bundgaard p.
25 113-191 (1991);
d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992);
e) H. Bundgaard, *et al.*, Journal of Pharmaceutical Sciences, 77, 285 (1988); and
f) N. Kakeya, *et al.*, Chem Pharm Bull, 32, 692 (1984).

The contents of the above cited documents are incorporated herein by reference.

- 30 Examples of pro-drugs are as follows. An *in vivo* hydrolysable ester of a compound of the invention containing a carboxy or a hydroxy group is, for example, a pharmaceutically-acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol. Suitable pharmaceutically-acceptable esters for carboxy include

C₁-C₆alkoxymethyl esters for example methoxymethyl, C₁-C₆alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C₃-C₈cycloalkoxycarbonyloxyC₁-C₆alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters, for example 5-methyl-1,3-dioxolen-2-onylmethyl; and C₁-C₆alkoxycarbonyloxyethyl esters.

- 5 An *in vivo* hydrolysable ester of a compound of the invention containing a hydroxy group includes inorganic esters such as phosphate esters (including phosphoramidic cyclic esters) and α -acyloxyalkyl ethers and related compounds which as a result of the *in vivo* hydrolysis of the ester breakdown to give the parent hydroxy group/s. Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy.
- 10 A selection of *in vivo* hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and *N*-(dialkylaminoethyl)-*N*-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl.

 A suitable pharmaceutically-acceptable salt of a compound of the invention is, for
15 example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid. In addition a suitable pharmaceutically-acceptable salt of a benzoxazinone derivative of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or
20 potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

 A further feature of the invention is a pharmaceutical composition comprising a
25 compound of formula (I) as defined above, or a salt, solvate or prodrug thereof, together with a pharmaceutically-acceptable diluent or carrier.

 According to another aspect of the invention there is provided a compound of formula (I) as defined above for use as a medicament.

 Further according to the invention there is provided a compound of formula (I) for use
30 in the preparation of a medicament for treatment of a disease mediated through GLK, in particular type 2 diabetes.

 The compound is suitably formulated as a pharmaceutical composition for use in this way.

According to another aspect of the present invention there is provided a method of treating GLK mediated diseases, especially type 2 diabetes, by administering an effective amount of a compound of formula (I), or salt, solvate or pro-drug thereof, to a mammal in need of such treatment.

5 Specific disease which may be treated by the compound or composition of the invention include: blood glucose lowering in diabetes mellitus type 2 without a serious risk of hypoglycaemia (and potential to treat type 1), dyslipidemia, obesity, insulin resistance, metabolic syndrome X, impaired glucose tolerance.

As discussed above, thus the GLK/GLKRP system can be described as a potential
10 “diabesity” target (of benefit in both diabetes and obesity). Thus, according to another aspect of the invention there is provided the use of a compound of formula (I), or salt, solvate or pro-drug thereof, in the preparation of a medicament for use in the combined treatment or prevention of diabetes and obesity.

According to another aspect of the invention there is provided the use of a compound of
15 formula (I), or salt, solvate or pro-drug thereof, in the preparation of a medicament for use in the treatment or prevention of obesity.

According to a further aspect of the invention there is provided a method for the combined treatment of obesity and diabetes by administering an effective amount of a compound of formula (I), or salt, solvate or pro-drug thereof, to a mammal in need of such
20 treatment.

According to a further aspect of the invention there is provided a method for the treatment of obesity by administering an effective amount of a compound of formula (I), or salt, solvate or pro-drug thereof, to a mammal in need of such treatment.

The compositions of the invention may be in a form suitable for oral use (for example
25 as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile
30 aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).

The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended

- 11 -

for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.

Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding
5 agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the
10 gastrointestinal tract, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.

Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with
15 water or an oil such as peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation
20 products of an alkylene oxide with fatty acids (for example polyoxethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example
25 heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-
30 oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid

paraffin). The oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

5 Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present.

10 The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these. Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial
15 esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavouring and preservative agents.

 Syrups and elixirs may be formulated with sweetening agents such as glycerol,
20 propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.

 The pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been
25 mentioned above. A sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.

 Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing
30 finely divided solid or liquid droplets. Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.

For further information on formulation the reader is referred to Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

The amount of active ingredient that is combined with one or more excipients to
5 produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition. Dosage unit forms will
10 generally contain about 1 mg to about 500 mg of an active ingredient. For further information on Routes of Administration and Dosage Regimes the reader is referred to Chapter 25.3 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

The size of the dose for therapeutic or prophylactic purposes of a compound of the
15 formula (I) will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine.

In using a compound of the formula (I) for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, 0.5 mg to 75 mg per
20 kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous administration, a dose in the range, for example, 0.5 mg to 30 mg per kg body weight will generally be used. Similarly, for administration by inhalation, a dose in the range, for example, 0.5 mg to 25 mg per kg body weight will be used. Oral administration is however
25 preferred.

The elevation of GLK activity described herein may be applied as a sole therapy or may involve, in addition to the subject of the present invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment.
30 Simultaneous treatment may be in a single tablet or in separate tablets. For example in the treatment of diabetes mellitus chemotherapy may include the following main categories of treatment:


- 14 -

- 1) Insulin and insulin analogues;
 - 2) Insulin secretagogues including sulphonylureas (for example glibenclamide, glipizide) and prandial glucose regulators (for example repaglinide, nateglinide);
 - 3) Insulin sensitising agents including PPAR γ agonists (for example pioglitazone and
5 rosiglitazone);
 - 4) Agents that suppress hepatic glucose output (for example metformin).
 - 5) Agents designed to reduce the absorption of glucose from the intestine (for example acarbose);
 - 6) Agents designed to treat the complications of prolonged hyperglycaemia;
 - 10 7) Anti-obesity agents (for example sibutramine and orlistat);
 - 8) Anti-dyslipidaemia agents such as, HMG-CoA reductase inhibitors (statins, e.g. pravastatin); PPAR α agonists (fibrates, eg gemfibrozil); bile acid sequestrants (cholestyramine); cholesterol absorption inhibitors (plant stanols, synthetic inhibitors); bile acid absorption inhibitors (IBATi) and nicotinic acid and analogues (niacin and slow release
15 formulations);
 - 9) Antihypertensive agents such as, β blockers (eg atenolol, inderal); ACE inhibitors (eg lisinopril); Calcium antagonists (eg. nifedipine); Angiotensin receptor antagonists (eg candesartan), α antagonists and diuretic agents (eg. furosemide, benzthiazide);
 - 10) Haemostasis modulators such as, antithrombotics, activators of fibrinolysis and
20 antiplatelet agents; thrombin antagonists; factor Xa inhibitors; factor VIIa inhibitors); antiplatelet agents (eg. aspirin, clopidogrel); anticoagulants (heparin and Low molecular weight analogues, hirudin) and warfarin; and
 - 11) Anti-inflammatory agents, such as non-steroidal anti-inflammatory drugs (eg. aspirin) and steroidal anti-inflammatory agents (eg. cortisone).
- 25 According to another aspect of the present invention there is provided individual compounds produced as end products in the Examples set out below and salts, solvates and pro-drugs thereof.


Another aspect of the present invention provides a process for preparing a compound of formula (I) or a salt, solvate or pro-drug thereof which process (wherein variable groups
30 are, unless otherwise specified, as defined in formula (I)) comprises:

- 15 -


Process 1): reacting an acid of formula (II):



or an activated derivative thereof; with a compound of formula (III): or



Process 2) for compounds of formula (I) wherein R⁴ is carboxy; deprotecting a compound of formula (III):



wherein RˣC(O)O- is an ester group;

and thereafter if necessary or desirable:

i) converting a compound of the formula (I) into another compound of the formula (I), and or;

ii) removing any protecting groups; and/or

15 iii) forming a salt, solvate or pro-drug thereof.

Suitable activated acid derivatives include acid halides, for example acid chlorides, and active esters, for example pentafluorophenyl esters. The reaction of these types of compounds with amines is well known in the art.

The group RˣOC(O)- is an ester. Suitable values for Rˣ are C₁₋₆alkyl and benzyl,
20 particularly methyl and ethyl.

- 16 -

The reactions described above may be performed under standard conditions. The intermediates described above are commercially available, are known in the art or may be prepared by known procedures.

Some of the intermediates described herein are novel and are thus provided as a
5 further feature of the invention. For example compounds of formula (III) are provided as a further feature of the invention.

During the preparation process, it may be advantageous to use a protecting group. Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in
10 question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.

Specific examples of protecting groups are given below for the sake of convenience, in which "lower" signifies that the group to which it is applied preferably has 1-4 carbon atoms. It will be understood that these examples are not exhaustive. Where specific examples of
15 methods for the removal of protecting groups are given below these are similarly not exhaustive. The use of protecting groups and methods of deprotection not specifically mentioned is of course within the scope of the invention.

A carboxy protecting group may be the residue of an ester-forming aliphatic or araliphatic alcohol or of an ester-forming silanol (the said alcohol or silanol preferably
20 containing 1-20 carbon atoms). Examples of carboxy protecting groups include straight or branched chain C₁₋₁₂alkyl groups (e.g. isopropyl, *t*-butyl); lower alkoxy lower alkyl groups (e.g. methoxymethyl, ethoxymethyl, isobutoxymethyl; lower aliphatic acyloxy lower alkyl groups, (e.g. acetoxymethyl, propionyloxymethyl, butyryloxymethyl, pivaloyloxymethyl); lower alkoxycarbonyloxy lower alkyl groups (e.g. 1-methoxycarbonyloxyethyl,
25 1-ethoxycarbonyloxyethyl); aryl lower alkyl groups (e.g. *p*-methoxybenzyl, *o*-nitrobenzyl, *p*-nitrobenzyl, benzhydryl and phthalidyl); tri(lower alkyl)silyl groups (e.g. trimethylsilyl and *t*-butyldimethylsilyl); tri(lower alkyl)silyl lower alkyl groups (e.g. trimethylsilylethyl); and C₂₋₆alkenyl groups (e.g. allyl and vinyloethyl).

Methods particularly appropriate for the removal of carboxyl protecting groups include
30 for example acid-, metal- or enzymically-catalysed hydrolysis.

Examples of hydroxy protecting groups include lower alkenyl groups (e.g. allyl); lower alkanoyl groups (e.g. acetyl); lower alkoxycarbonyl groups (e.g. *t*-butoxycarbonyl); lower alkenyloxycarbonyl groups (e.g. allyloxycarbonyl); aryl lower alkoxycarbonyl groups (e.g.

- 17 -

benzoyloxycarbonyl, *p*-methoxybenzyloxycarbonyl, *o*-nitrobenzyloxycarbonyl, *p*-nitrobenzyloxycarbonyl); tri lower alkyl/arylsilyl groups (e.g. trimethylsilyl, *t*-butyldimethylsilyl, *t*-butyldiphenylsilyl); aryl lower alkyl groups (e.g. benzyl) groups; and triaryl lower alkyl groups (e.g. triphenylmethyl).

- 5 Examples of amino protecting groups include formyl, aralkyl groups (e.g. benzyl and substituted benzyl, e.g. *p*-methoxybenzyl, nitrobenzyl and 2,4-dimethoxybenzyl, and triphenylmethyl); di-*p*-anisylmethyl and furylmethyl groups; lower alkoxycarbonyl (e.g. *t*-butoxycarbonyl); lower alkenyloxycarbonyl (e.g. allyloxycarbonyl); aryl lower alkoxycarbonyl groups (e.g. benzyloxycarbonyl, *p*-methoxybenzyloxycarbonyl, *o*-nitrobenzyloxycarbonyl, *p*-nitrobenzyloxycarbonyl); trialkylsilyl (e.g. trimethylsilyl and *t*-butyldimethylsilyl); alkylidene (e.g. methylenidene); benzylidene and substituted benzylidene groups.

- Methods appropriate for removal of hydroxy and amino protecting groups include, for example, acid-, base, metal- or enzymically-catalysed hydrolysis, or photolytically for groups
 15 such as *o*-nitrobenzyloxycarbonyl, or with fluoride ions for silyl groups.

- Examples of protecting groups for amide groups include aralkoxymethyl (e.g. benzyloxymethyl and substituted benzyloxymethyl); alkoxymethyl (e.g. methoxymethyl and trimethylsilylethoxymethyl); tri alkyl/arylsilyl (e.g. trimethylsilyl, *t*-butyldimethylsilyl, *t*-butyldiphenylsilyl); tri alkyl/arylsilyloxymethyl (e.g. *t*-butyldimethylsilyloxymethyl, *t*-butyldiphenylsilyloxymethyl); 4-alkoxyphenyl (e.g. 4-methoxyphenyl); 2,4-di(alkoxy)phenyl (e.g. 2,4-dimethoxyphenyl); 4-alkoxybenzyl (e.g. 4-methoxybenzyl); 2,4-di(alkoxy)benzyl (e.g. 2,4-di(methoxy)benzyl); and alk-1-enyl (e.g. allyl, but-1-enyl and substituted vinyl e.g. 2-phenylvinyl).

- Aralkoxymethyl, groups may be introduced onto the amide group by reacting the latter
 25 group with the appropriate aralkoxymethyl chloride, and removed by catalytic hydrogenation. Alkoxymethyl, tri alkyl/arylsilyl and tri alkyl/silyloxymethyl groups may be introduced by reacting the amide with the appropriate chloride and removing with acid; or in the case of the silyl containing groups, fluoride ions. The alkoxyphenyl and alkoxybenzyl groups are conveniently introduced by arylation or alkylation with an appropriate halide and removed by
 30 oxidation with ceric ammonium nitrate. Finally alk-1-enyl groups may be introduced by reacting the amide with the appropriate aldehyde and removed with acid.

BIOLOGICAL**Tests:**

The biological effects of the compounds of formula (I) may be tested in the following way:

- 5 (1) Enzymatic activity of GLK may be measured by incubating GLK, ATP and glucose. The rate of product formation may be determined by coupling the assay to a G-6-P dehydrogenase, NADP/NADPH system and measuring the increase in optical density at 340nm (Matschinsky et al 1993).
- (2) A GLK/GLKRP binding assay for measuring the binding interactions between GLK and
10 GLKRP. The method may be used to identify compounds which modulate GLK by modulating the interaction between GLK and GLKRP. GLKRP and GLK are incubated with an inhibitory concentration of F-6-P, optionally in the presence of test compound, and the extent of interaction between GLK and GLKRP is measured. Compounds which either displace F-6-P or in some other way reduce the GLK/GLKRP interaction will be detected by a
15 decrease in the amount of GLK/GLKRP complex formed. Compounds which promote F-6-P binding or in some other way enhance the GLK/GLKRP interaction will be detected by an increase in the amount of GLK/GLKRP complex formed. A specific example of such a binding assay is described below.

20 *GLK/GLKRP scintillation proximity assay*

Compounds of the invention were found to have an activity of less than 10 μ m when tested in the GLK/GLKRP scintillation proximity assay described below.

- Recombinant human GLK and GLKRP were used to develop a "mix and measure" 96 well SPA (scintillation proximity assay) as described in WO01/20327 (the contents of which
25 are incorporated herein by reference). GLK (Biotinylated) and GLKRP are incubated with streptavidin linked SPA beads (Amersham) in the presence of an inhibitory concentration of radiolabelled [3H]F-6-P (Amersham Custom Synthesis TRQ8689), giving a signal. Compounds which either displace the F-6-P or in some other way disrupt the GLK / GLKRP binding interaction will cause this signal to be lost.

- 30 Binding assays were performed at room temperature for 2 hours. The reaction mixtures contained 50mM Tris-HCl (pH 7.5), 2mM ATP, 5mM MgCl₂, 0.5mM DTT, recombinant biotinylated GLK (0.1 mg), recombinant GLKRP (0.1 mg), 0.05mCi [3H] F-6-P (Amersham) to give a final volume of 100ml. Following incubation, the extent of

- 19 -

GLK/GLKRP complex formation was determined by addition of 0.1mg/well avidin linked SPA beads (Amersham) and scintillation counting on a Packard TopCount NXT.

(3) A F-6-P / GLKRP binding assay for measuring the binding interaction between GLKRP and F-6-P. This method may be used to provide further information on the mechanism of action of the compounds. Compounds identified in the GLK/GLKRP binding assay may modulate the interaction of GLK and GLKRP either by displacing F-6-P or by modifying the GLK/GLKRP interaction in some other way. For example, protein-protein interactions are generally known to occur by interactions through multiple binding sites. It is thus possible that a compound which modifies the interaction between GLK and GLKRP could act by binding to one or more of several different binding sites.

The F-6-P / GLKRP binding assay identifies only those compounds which modulate the interaction of GLK and GLKRP by displacing F-6-P from its binding site on GLKRP.

GLKRP is incubated with test compound and an inhibitory concentration of F-6-P, in the absence of GLK, and the extent of interaction between F-6-P and GLKRP is measured. Compounds which displace the binding of F-6-P to GLKRP may be detected by a change in the amount of GLKRP/F-6-P complex formed. A specific example of such a binding assay is described below.

F-6-P / GLKRP scintillation proximity assay

Recombinant human GLKRP was used to develop a "mix and measure" 96 well scintillation proximity assay) as described in WO01/20327 (the contents of which are incorporated herein by reference). FLAG-tagged GLKRP is incubated with protein A coated SPA beads (Amersham) and an anti-FLAG antibody in the presence of an inhibitory concentration of radiolabelled [3H]F-6-P. A signal is generated. Compounds which displace the F-6-P will cause this signal to be lost. A combination of this assay and the GLK/GLKRP binding assay will allow the observer to identify compounds which disrupt the GLK/GLKRP binding interaction by displacing F-6-P.

Binding assays were performed at room temperature for 2 hours. The reaction mixtures contained 50mM Tris-HCl (pH 7.5), 2mM ATP, 5mM MgCl₂, 0.5mM DTT, recombinant FLAG tagged GLKRP (0.1 mg), Anti-Flag M2 Antibody (0.2mg) (IBI Kodak), 0.05mCi [3H] F-6-P (Amersham) to give a final volume of 100ml. Following incubation, the extent of F-6-P/GLKRP complex formation was determined by addition of 0.1mg/well protein A linked SPA beads (Amersham) and scintillation counting on a Packard TopCount NXT.

Production of recombinant GLK and GLKRP:

Preparation of mRNA

Human liver total mRNA was prepared by polytron homogenisation in 4M guanidine
5 isothiocyanate, 2.5mM citrate, 0.5% Sarkosyl, 100mM b-mercaptoethanol, followed by
centrifugation through 5.7M CsCl, 25mM sodium acetate at 135,000g (max) as described in
Sambrook J, Fritsch EF & Maniatis T, 1989.

Poly A⁺ mRNA was prepared directly using a FastTrack™ mRNA isolation kit
(Invitrogen).

10

PCR amplification of GLK and GLKRP cDNA sequences

Human GLK and GLKRP cDNA was obtained by PCR from human hepatic mRNA
using established techniques described in Sambrook, Fritsch & Maniatis, 1989. PCR primers
were designed according to the GLK and GLKRP cDNA sequences shown in Tanizawa et al
15 1991 and Bonthron, D.T. *et al* 1994 (later corrected in Warner, J.P. 1995).

Cloning in Bluescript II vectors

GLK and GLKRP cDNA was cloned in E. coli using pBluescript II, (Short et al 1998)
a recombinant cloning vector system similar to that employed by Yanisch-Perron C *et al*
20 (1985), comprising a colEI-based replicon bearing a polylinker DNA fragment containing
multiple unique restriction sites, flanked by bacteriophage T3 and T7 promoter sequences; a
filamentous phage origin of replication and an ampicillin drug resistance marker gene.

Transformations

25 E. Coli transformations were generally carried out by electroporation. 400 ml cultures
of strains DH5a or BL21(DE3) were grown in L-broth to an OD 600 of 0.5 and harvested by
centrifugation at 2,000g. The cells were washed twice in ice-cold deionised water,
resuspended in 1ml 10% glycerol and stored in aliquots at -70°C. Ligation mixes were
desalted using Millipore V series™ membranes (0.0025mm) pore size). 40ml of cells were
30 incubated with 1ml of ligation mix or plasmid DNA on ice for 10 minutes in 0.2cm
electroporation cuvettes, and then pulsed using a Gene Pulser™ apparatus (BioRad) at
0.5kVcm⁻¹, 250mF, 250. Transformants were selected on L-agar supplemented with
tetracycline at 10mg/ml or ampicillin at 100mg/ml.

Expression

GLK was expressed from the vector pTB375NBSE in E.coli BL21 cells,, producing a recombinant protein containing a 6-His tag immediately adjacent to the N-terminal methionine. Alternatively, another suitable vector is pET21(+)DNA, Novagen, Cat number 697703. The 6-His tag was used to allow purification of the recombinant protein on a column packed with nickel-nitrilotriacetic acid agarose purchased from Qiagen (cat no 30250).

GLKRP was expressed from the vector pFLAG CTC (IBI Kodak) in E.coli BL21 cells, producing a recombinant protein containing a C-terminal FLAG tag. The protein was purified initially by DEAE Sepharose ion exchange followed by utilisation of the FLAG tag for final purification on an M2 anti-FLAG immunoaffinity column purchased from Sigma-Aldrich (cat no. A1205).

Biotinylation of GLK:

GLK was biotinylated by reaction with biotinamidocaproate N-hydroxysuccinimide ester (biotin-NHS) purchased from Sigma-Aldrich (cat no. B2643). Briefly, free amino groups of the target protein (GLK) are reacted with biotin-NHS at a defined molar ratio forming stable amide bonds resulting in a product containing covalently bound biotin. Excess, non-conjugated biotin-NHS is removed from the product by dialysis. Specifically, 7.5mg of GLK was added to 0.31mg of biotin-NHS in 4mL of 25mM HEPES pH7.3, 0.15M KCl, 1mM dithiothreitol, 1mM EDTA, 1mM MgCl₂ (buffer A). This reaction mixture was dialysed against 100mL of buffer A containing a further 22mg of biotin-NHS. After 4hours excess biotin-NHS was removed by extensive dialysis against buffer A.

The following examples are for illustration purposes and are not intended to limit the scope of this application. Each exemplified compound represents a particular and independent aspect of the invention. In the following non-limiting Examples, unless otherwise stated:

- (i) evaporations were carried out by rotary evaporation *in vacuo* and work-up procedures were carried out after removal of residual solids such as drying agents by filtration;
- (ii) operations were carried out at room temperature, that is in the range 18-25°C and under an atmosphere of an inert gas such as argon or nitrogen;
- (iii) yields are given for illustration only and are not necessarily the maximum attainable;

- 22 -

(iv) the structures of the end-products of the formula (I) were confirmed by nuclear (generally proton) magnetic resonance (NMR) and mass spectral techniques; proton magnetic resonance chemical shift values were measured on the delta scale in deuterated dimethyl sulfoxide unless otherwise stated, and peak multiplicities are shown as follows: s, singlet; d, doublet; t, triplet; m, multiplet; br, broad; q, quartet, quin, quintet;

(v) intermediates were not generally fully characterised and purity was assessed by thin layer chromatography (TLC), high-performance liquid chromatography (HPLC), infra-red (IR) or NMR analysis;

(vi) chromatography was performed on silica (Merck Silica gel 60, 0.040 - 0.063 mm, 230 - 400 mesh); and

(vi) where a "Bondelut" column is referred to, this means a column containing 10 g or 20 g or 50 g or 70g of silica of 40 micron particle size, the silica being contained in a 60 ml disposable syringe and supported by a porous disc, obtained from Varian, Harbor City, California, USA under the name "Mega Bond Elut SP"; "Mega Bond Elut" is a trademark;

(vii) the following abbreviations are used:

DCM	dichloromethane;
DMF	dimethylformamide;
LCMS	liquid chromatography / mass spectroscopy;
THF	tetrahydrofuran.






Example 1


2-Methyl-4-isobutoxy-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran

Sodium hydroxide solution (0.94ml of 1M, 0.94 mM) was added to a solution of 2-methyl-4-isobutoxy-6-[N-(5-methoxycarbonylpyridin-2-yl)carbamoyl]benzofuran (Method 1; 120mg, 0.314 mM) in a methanol / THF mixture (1ml + 4ml), and the resulting solution stirred at ambient temperature. After 4hrs the reaction mixture was diluted with water (5 ml) and concentrated to half volume *in vacuo*. The resulting mixture was acidified to pH6 with 1M HCl. The resulting solid precipitate was filtered, washed with water, and dried to give a pale cream solid. This was chromatographed (10g Bondelut), eluting with DCM containing methanol (0 – 10% gradient) to give the title compound as a colourless solid. NMR: 1.03 (d, 6H), 2.09 (sept, 1H), 2.45 (s, 3H), 3.97 (d, 2H), 6.66 (s, 1H), 7.44 (s, 1H), 7.85 (s, 1H), 8.31 (t, 2H), 8.87 (s, 1H), 11.10 (bs, 1H); m/z 367 (M+H)⁺.

Examples 2-7


The following compounds were prepared by the procedure of Example 1 starting from the appropriate ester.

Ex	Structure	NMR	MS	SM
2		2.46 (s, 3H), 5.39 (s, 2H), 6.71 (s, 1H), 7.26 (m, 2H), 7.43 (m, 1H), 7.65 (m, 2H), 7.91 (s, 1H), 8.31 (m, 2H), 8.88 (s, 1H), 11.14 (bs, 1H), COOH not seen	(M+H) ⁺ 421	Method 17
3		1.03 (d, 6H), 2.10 (sept, 1H), 2.46 (s, 3H), 3.96 (d, 2H), 6.66 (s, 1H), 7.51 (s, 1H), 7.92 (s, 1H), 8.14 (s, 1H), 12.20 (bs, 1H), COOH not seen	(2M+H) ⁺ + 749	Method 18
4		2.44 (s, 3H), 2.49 (s, 3H), 5.43 (s, 2H), 6.42 (s, 1H), 6.71 (s, 1H), 7.66 (s, 1H), 7.93 (s, 1H), 8.36 (m, 2H), 8.90 (s, 1H), 13.10 (bs, 1H), COOH not seen	(M+H) ⁺ 408	Method 19
5		5.41 (s, 2H), 7.03 (s, 1H), 7.30 (m, 2H), 7.44 (m, 1H), 7.64 (m, 2H), 8.00 (s, 1H), 8.08 (d, 1H), 8.33 (m, 2H), 8.89 (s, 1H), 11.21 (bs, 1H), COOH not seen	(M+H) ⁺ 407 (M-H) ⁻ 405	Method 20
6		2.42 (s, 3H), 5.43 (s, 2H), 6.41 (s, 1H), 7.04 (d, 1H), 7.65 (s, 1H), 8.00 (s, 1H), 8.10 (d, 1H), 8.33 (m, 2H), 8.88 (s, 1H), 11.37 (bs, 1H), COOH not seen	(M+H) ⁺ 394 (M-H) ⁻ 392	Method 21

Ex	Structure	NMR	MS	SM
7		2.44 (s, 3H), 3.13 (t, 2H), 4.41 (t, 2H), 6.64 (s, 1H), 7.14 (d, 1H), 7.35 (m, 1H), 7.47 (m, 2H), 7.84 (s, 1H), 8.32 (m, 2H), 8.86 (s, 1H), 11.12 (bs, 1H), COOH not seen	(M+H) ⁺ 423	Method 22

Example 8

The following compound was prepared by the procedure of Method 1 using 2-aminothiazole.

Ex	Structure	NMR	MS
8		1.07 (d, 6H), 2.30 (sept, 1H), 2.50 (s, 3H), 4.01 (d, 2H), 6.60 (s, 1H), 7.27 (d, 1H), 7.52 (s, 1H), 7.58 (d, 1H), 7.92 (s, 1H), 12.56 (bs, 1H)	(M+H) ⁺ 331 (2M+H) + 661

5

Preparation of Starting Materials

The starting materials for the Examples above are either commercially available or are readily prepared by standard methods from known materials. For example the following reactions are illustrations but not limitations of the preparation of some of the starting materials used in the above reactions.

Method 1**2-Methyl-4-isobutoxy-6-[N-(5-methoxycarbonylpyridin-2-yl)carbamoyl]benzofuran**

Oxalyl chloride (410mg, 282μl, 3.225 mmol, 5 eq) was added to a solution of 2-methyl-4-isobutoxy-6-carboxybenzofuran (Method 2; 0.160mg, 0.645 mmol) in DCM (5ml) and the reaction mixture stirred for 4 hrs at ambient temperature. Further reagent was added, the reaction mixture stirred for 16hrs, and then warmed to 40°C. As starting acid still remained, the solvent was removed *in vacuo* and the residue treated with neat oxalyl chloride. The reaction mixture was then concentrated *in vacuo* and dissolved in pyridine (5ml); to the resulting solution was added methyl 2-aminopyridine-5-carboxylate (98mg, 0.645 mmol).

20

- 25 -

After stirring for 16hrs the reddish solution was concentrated *in vacuo* and the resulting gum dissolved in DCM and chromatographed (20g Bondelut, eluting with hexane containing ethyl acetate, 0 – 100%) to give the title compound (122mg, 49.5% yield) as a colourless gum which slowly set solid; LC-MS 383 (M+H)⁺, 94.4% strength.

5

Method 2**2-Methyl-4-isobutoxy-6-carboxybenzofuran**

Sodium hydroxide solution (2.28ml of 1M, 2.28 mmol, 3 eq) was added to a solution of 2-methyl-4-isobutoxy-6-methoxycarbonylbenzofuran (Method 7; 200mg, 0.76 mmol; 10 contained ca 15 mol% of isobutyl ester) in MeOH (2.28ml)/THF (2.28ml). After 2 hours at 50°C the reaction mixture was stirred at ambient temperature overnight and then concentrated to half-volume *in vacuo*. The resulting solution was diluted with water and acidified to pH 5 (1M HCl), and the resulting flocculent precipitate filtered and dried to give the title compound as a colourless solid (165mg, 88%). NMR: 1.02 (d, 6H), 2.06 (sept, 1H), 2.45 (s, 3H), 3.90 (d, 15 2H), 6.64 (s, 1H), 7.24 (s, 1H), 7.64 (s, 1H), 12.83 (bs, 1H); m/z 247 (M-H)⁻, 94.6% by LC-MS.

Methods 3-6

The following compounds were prepared by the procedure of Method 2.

Method	Compound	SM
3	2-Methyl-4-(2-fluorobenzyloxy)-6-carboxybenzofuran	Method 8
4	2-Methyl-4-(5-methylisoxazol-3-ylmethoxy)-6-carboxybenzofuran	Method 9
5	4-(2-Fluorobenzyloxy)-6-carboxybenzofuran	Method 10
6	4-(5-Methylisoxazol-3-ylmethoxy)-6-carboxybenzofuran	Method 11

20

Method 7**2-Methyl-4-isobutoxy-6-methoxycarbonylbenzofuran**

2-Methyl-4-hydroxy-6-methoxycarbonylbenzofuran (Method 12; 412mg, assumed 1.0mmol) was stirred in anhydrous DMF (10ml) and the solution treated sequentially with 25 potassium carbonate (690mg, 5mmol, 5 eq) and 1-iodo-2-methylpropane (442mg, 276μl, 2.4

- 26 -

mmol, 2.4 eq). The reaction mixture was stirred at 90°C for 3 hours, then cooled and poured into water; the resulting mixture was extracted twice with ethyl acetate, the extracts dried (MgSO₄) and evaporated *in vacuo* to yield a brown oil. This was chromatographed (50g Bondelut, eluting with hexane containing ethyl acetate, 0 – 100%) to give the title compound
 5 as a clear oil contaminated with ca 15% of the corresponding iso-butyl ester. NMR: 1.02 (d, 6H), 2.06 (sept, 1H), 2.45 (s, 3H), 3.84 (s, 3H), 3.91 (d, 2H), 6.66 (s, 1H), 7.24 (s, 1H), 7.66 (s, 1H); the spectrum also contained signals consistent with isobutyl ester, ca 15 mol%.

Methods 8-11

10 The following compounds were prepared by the procedure of Method 7.

Method	Compound	SM
8	2-Methyl-4-(2-fluorobenzyloxy)-6-methoxycarbonylbenzofuran	Method 12
9	2-Methyl-4-(5-methylisoxazol-3-ylmethoxy)-6-methoxycarbonylbenzofuran	Method 12
10	4-(2-Fluorobenzyloxy)-6-methoxycarbonylbenzofuran	Method 13
11	4-(5-Methylisoxazol-3-ylmethoxy)-6-methoxycarbonylbenzofuran	Method 13

Method 12

2-Methyl-4-hydroxy-6-methoxycarbonylbenzofuran

2-Methyl-4-acetoxy-6-methoxycarbonylbenzofuran (Method 14; 1.275g, 5.14 mmol)
 15 was added to a suspension of potassium carbonate (1.408g, 10.3 mmol, 2 eq) in MeOH (100ml) and water (2 ml), and the mixture stirred for 1 hr at ambient temperature. The supernatant liquor was decanted from the insoluble material and evaporated *in vacuo* to yield a cream solid (2.19g, assumed to be contaminated with inorganics). NMR: 2.35 (s, 3H), 3.56 (br s, 1H), 3.73 (s, 3H), 6.46 (s, 1H), 6.69 (s, 1H), 6.86 (s, 1H); m/z 205 (M-H)⁺, 83% by LC-
 20 MS.

Method 13

The following compound was prepared by the procedure of Method 12 starting from 4-acetoxy-6-methoxycarbonylbenzofuran (J Chem Soc (C); 1968, 867-9).

Method	Compound
13	4-Hydroxy-6-methoxycarbonylbenzofuran

5 Method 14**2-Methyl-4-acetoxy-6-methoxycarbonylbenzofuran**

A mixture of E-3-methoxycarbonyl-4-(5-methylfur-2-yl)-but-3-enoic acid (Method 15; 1.39g, 6.2 mmol) and potassium acetate (620mg, 6.3 mmol) in acetic anhydride (12.5 ml) was heated at 140°C for 15 mins. The reaction mixture was cooled and poured on to a
10 water/ethyl acetate mixture; the aqueous layer was separated and the organic layer washed sequentially with saturated sodium bicarbonate solution and brine, dried (MgSO₄) and evaporated *in vacuo* to yield the crude product as a dark crystalline mass. This was chromatographed (50g Bondelut, eluting with hexane containing ethyl acetate, 0 – 100%) to give the title compound as a pale yellow solid, 1.42g (92%). NMR: 2.36 (s, 3H), 3.34 (s, 3H),
15 3.87 (s, 3H), 6.68 (s, 1H), 7.56 (s, 1H), 7.96 (s, 1H); m/z 247 (M-H)⁺, 97.1% by LC-MS.

Method 15**E-3-Methoxycarbonyl-4-(5-methylfur-2-yl)-but-3-enoic acid**

A solution of E-3-methoxycarbonyl-4-(5-methylfur-2-yl)-but-3-enoic acid t-butyl ester
20 (Method 16; 1.39g, 4.96 mmol) in trifluoroacetic acid / water (20ml of 90:10 v/v) was stirred at ambient temperature for 20 mins; the reaction mixture was then diluted with toluene (30 ml) and evaporated *in vacuo* to yield a brown oil. After further azeotroping with toluene (30ml), this set solid; trituration with isohexane and collection of the residue yielded the title compound as a brown solid (1.05g, 95%). NMR 2.33 (s, 3H), 3.65 (s, 2H), 3.72 (s, 3H), 6.29
25 (d, 1H), 6.85 (d, 1H), 7.41 (s, 1H), 12.34 (bs, 1H).

Method 16**E-3-methoxycarbonyl-4-(5-methylfur-2-yl)-but-3-enoic acid t-butyl ester**

A solution of 1-methoxycarbonyl-2-t-butoxycarbonyl ethyl phosphorane (JCS Perkin
30 II, 1975, p1030; 2.69g, 6 mmol, 1.2 eq) and 5-methylfuran-2-al (0.5 ml, 5 mmol) in dry toluene (10 ml) was stirred at 80°C for 48 hrs, and then evaporated to dryness. The residue

- 28 -

was chromatographed (50g Bondelut, eluting with hexane containing 10% v/v ethyl acetate) to yield the title compound as a brown oil (1.39g, 100%). NMR: 1.38 (s, 9H), 2.33 (s, 3H), 3.62 (s, 2H), 3.71 (s, 3H), 6.31 (d, 1H), 6.85 (d, 1H), 7.42 (s, 1H).

5 Method 17

2-Methyl-4-(2-fluorobenzyloxy)-6-[N-(4-methoxycarbonylphenyl)carbamoyl]benzofuran

A solution of 2-methyl-4-(2-fluorobenzyloxy)-1-benzofuran-6-carboxylic acid (Method 3; 0.60mg, 0.2 mmol) and methyl 2-aminopyridine-5-carboxylate (61mg, 0.4 mmol, 2 eq) in pyridine (1ml) was treated with phosphorus oxychloride (20.5 μ l, 0.22 mmol, 1.1 eq), and the reaction mixture stirred for 16 hrs at ambient temperature. The reaction mixture was poured into water and extracted twice with ethyl acetate; the extracts were washed with brine, dried (MgSO₄) and evaporated to give a yellow gum. This was chromatographed (10g Bondelut, eluting with hexane containing ethyl acetate, 0 – 100%) to give the title compound as a solid (61mg, 70%). NMR: 2.46 (s, 3H), 3.87 (s, 3H), 5.37 (s, 2H), 6.66 (s, 1H), 7.25 (m, 2H), 7.42 (m, 1H), 7.62 (m, 2H), 7.91 (s, 1H), 8.36 (m, 2H), 8.91 (s, 1H), 11.20 (bs, 1H); m/z 435 (M+H)⁺, 100% by LC-MS.

Methods 18-22

The following compounds were prepared by the procedure of Method 17.

Method	Compound	SM
18	2-Methyl-4-isobutoxy-6-[N-(5-ethoxycarbonylthiazol-2-yl)carbamoyl]benzofuran	Method 2
19	2-Methyl-4-(5-methylisoxazol-3-ylmethoxy)-6-[N-(5-methoxycarbonylpyridin-2-yl)carbamoyl]benzofuran	Method 4
20	4-(2-Fluorobenzyloxy)-6-[N-(5-methoxycarbonylpyridin-2-yl)carbamoyl]benzofuran	Method 5
21	4-(5-Methylisoxazol-3-ylmethoxy)-6-[N-(5-methoxycarbonylpyridin-2-yl)carbamoyl]benzofuran	Method 6
22	2-Methyl-4-(2-thien-3-ylethoxy)-6-[N-(5-methoxycarbonylpyridin-2-yl)carbamoyl]benzofuran	Method 23

Method 23**2-Methyl-4-(2-thien-3-ylethoxy)-6-methoxycarbonylbenzofuran**

To a solution of 2-methyl-4-hydroxy-6-methoxycarbonylbenzofuran (Method 12; 1.24g, 6.0 mmol) and 2-(3-thienyl) ethanol (768 mg, 0.67 ml, 6.0 mmol) in DCM (DCM, 50ml) was added polymer-supported triphenyl phosphine (2.5g, ca 3 mmol/g, 1.5 eq), and the suspension cooled to 5°C under an argon atmosphere. To this was added di t-butyl azodicarboxylate (1.725g, 7.5 mmol, 1.5 eq), and the reaction mixture stirred overnight, allowing to warm to ambient temperature. It was then filtered through diatomaceous earth, washed through with DCM, and the filtrate and washings evaporated *in vacuo* to ~50ml total volume. To this was added trifluoroacetic acid (2ml), and the solution evaporated *in vacuo* to give a red oil. This was chromatographed (70g Bondelut, eluting with hexane containing ethyl acetate, 0 – 50%) to give a red solid; this was re-chromatographed (as previous) to give the title compound as a colourless crystalline solid (150mg, 8% yield). NMR: 2.46 (s, 3H), 3.10 (t, 2H), 3.83 (s, 3H), 4.33 (t, 2H), 6.64 (s, 1H), 7.12 (dd, 1H), 7.28 (s, 1H), 7.32 (d, 1H), 7.46 (dd, 1H), 7.66 (s, 1H).

Pharmaceutical Compositions

The following illustrate representative pharmaceutical dosage forms of the invention as defined herein (the active ingredient being termed "Compound X"), for therapeutic or prophylactic use in humans:

	(a)	<u>Tablet I</u>	<u>mg/tablet</u>
		Compound X.....	100
		Lactose Ph.Eur.....	182.75
		Croscarmellose sodium.....	12.0
25		Maize starch paste (5% w/v paste).....	2.25
		Magnesium stearate.....	3.0
	(b)	<u>Tablet II</u>	<u>mg/tablet</u>
		Compound X.....	50
		Lactose Ph.Eur.....	223.75
30		Croscarmellose sodium.....	6.0
		Maize starch.....	15.0
		Polyvinylpyrrolidone (5% w/v paste).....	2.25
		Magnesium stearate.....	3.0

- 30 -

5	(c) <u>Tablet III</u>	<u>mg/tablet</u>
	Compound X.....	1.0
	Lactose Ph.Eur.....	93.25
	Croscarmellose sodium.....	4.0
	Maize starch paste (5% w/v paste).....	0.75
10	Magnesium stearate.....	1.0
	(d) <u>Capsule</u>	<u>mg/capsule</u>
	Compound X.....	10
	Lactose Ph.Eur.....	488.5
	Magnesium.....	1.5
15	(e) <u>Injection I</u>	<u>(50 mg/ml)</u>
	Compound X.....	5.0% w/v
	1M Sodium hydroxide solution.....	15.0% v/v
	0.1M Hydrochloric acid (to adjust pH to 7.6)	
	Polyethylene glycol 400.....	4.5% w/v
20	Water for injection to 100%	
	(f) <u>Injection II</u>	<u>(10 mg/ml)</u>
	Compound X.....	1.0% w/v
	Sodium phosphate BP.....	3.6% w/v
	0.1M Sodium hydroxide solution.....	15.0% v/v
25	Water for injection to 100%	
	(g) <u>Injection III</u>	<u>(1mg/ml, buffered to pH6)</u>
	Compound X.....	0.1% w/v
	Sodium phosphate BP.....	2.26% w/v
	Citric acid.....	0.38% w/v
30	Polyethylene glycol 400.....	3.5% w/v
	Water for injection to 100%	
	(h) <u>Aerosol I</u>	<u>mg/ml</u>
	Compound X.....	10.0
	Sorbitan trioleate.....	13.5
30	Trichlorofluoromethane.....	910.0
	Dichlorodifluoromethane.....	490.0
	(i) <u>Aerosol II</u>	<u>mg/ml</u>

- 31 -

	Compound X.....	0.2
	Sorbitan trioleate.....	0.27
	Trichlorofluoromethane.....	70.0
	Dichlorodifluoromethane.....	280.0
5	Dichlorotetrafluoroethane.....	1094.0
(j)	<u>Aerosol III</u>	<u>mg/ml</u>
	Compound X.....	2.5
	Sorbitan trioleate.....	3.38
	Trichlorofluoromethane.....	67.5
10	Dichlorodifluoromethane.....	1086.0
	Dichlorotetrafluoroethane.....	191.6
(k)	<u>Aerosol IV</u>	<u>mg/ml</u>
	Compound X.....	2.5
	Soya lecithin.....	2.7
15	Trichlorofluoromethane.....	67.5
	Dichlorodifluoromethane.....	1086.0
	Dichlorotetrafluoroethane.....	191.6
(l)	<u>Ointment</u>	<u>ml</u>
	Compound X.....	40 mg
20	Ethanol.....	300 µl
	Water.....	300 µl
	1-Dodecylazacycloheptan-2-one.....	50 µl
	Propylene glycol.....	to 1 ml

Note

- 25 The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate. The aerosol formulations (h)-(k) may be used in conjunction with standard, metered dose aerosol dispensers, and the suspending agents sorbitan trioleate and soya lecithin may be replaced by an alternative
- 30 suspending agent such as sorbitan monooleate, sorbitan sesquioleate, polysorbate 80, polyglycerol oleate or oleic acid.

References


- 1 Printz, R. L., Magnuson, M. A. and Granner, D. K. (1993) Annual Review of Nutrition **13**, 463-96
- 2 DeFronzo, R. A. (1988) Diabetes **37**, 667-87
- 5 3 Froguel, P., Zouali, H., Vionnet, N., Velho, G., Vaxillaire, M., Sun, F., Lesage, S., Stoffel, M., Takeda, J. and Passa, P. (1993) New England Journal of Medicine **328**, 697-702
- 4 Bell, G. I., Pilkis, S. J., Weber, I. T. and Polonsky, K. S. (1996) Annual Review of Physiology **58**, 171-86
- 5 Velho, G., Petersen, K. F., Perseghin, G., Hwang, J. H., Rothman, D. L., Pueyo, M. E.,
- 10 Cline, G. W., Froguel, P. and Shulman, G. I. (1996) Journal of Clinical Investigation **98**, 1755-61
- 6 Christesen, H. B., Jacobsen, B. B., Odili, S., Buettger, C., Cuesta-Munoz, A., Hansen, T., Brusgaard, K., Massa, O., Magnuson, M. A., Shiota, C., Matschinsky, F. M. and Barbetti, F. (2002) Diabetes **51**, 1240-6
- 15 7 Glaser, B., Kesavan, P., Heyman, M., Davis, E., Cuesta, A., Buchs, A., Stanley, C. A., Thornton, P. S., Permutt, M. A., Matschinsky, F. M. and Herold, K. C. (1998) New England Journal of Medicine **338**, 226-30
- 8 Caro, J. F., Triester, S., Patel, V. K., Tapscott, E. B., Frazier, N. L. and Dohm, G. L. (1995) Hormone & Metabolic Research **27**, 19-22
- 20 9 Desai, U. J., Slosberg, E. D., Boettcher, B. R., Caplan, S. L., Fanelli, B., Stephan, Z., Gunther, V. J., Kaleko, M. and Connelly, S. (2001) Diabetes **50**, 2287-95
- 10 Shiota, M., Postic, C., Fujimoto, Y., Jetton, T. L., Dixon, K., Pan, D., Grimsby, J., Grippo, J. F., Magnuson, M. A. and Cherrington, A. D. (2001) Diabetes **50**, 622-9
- 11 Ferre, T., Pujol, A., Riu, E., Bosch, F. and Valera, A. (1996) Proceedings of the
- 25 National Academy of Sciences of the United States of America **93**, 7225-30
- 12 Seoane, J., Barbera, A., Telemaque-Potts, S., Newgard, C. B. and Guinovart, J. J. (1999) Journal of Biological Chemistry **274**, 31833-8
- 13 Moore, M. C., Davis, S. N., Mann, S. L. and Cherrington, A. D. (2001) Diabetes Care **24**, 1882-7
- 30 14 Alvarez, E., Roncero, I., Chowen, J. A., Vazquez, P. and Blazquez, E. (2002) Journal of Neurochemistry **80**, 45-53
- 15 Lynch, R. M., Tompkins, L. S., Brooks, H. L., Dunn-Meynell, A. A. and Levin, B. E. (2000) Diabetes **49**, 693-700

- 16 Roncero, I., Alvarez, E., Vazquez, P. and Blazquez, E. (2000) *Journal of Neurochemistry* **74**, 1848-57
- 17 Yang, X. J., Kow, L. M., Funabashi, T. and Mobbs, C. V. (1999) *Diabetes* **48**, 1763-1772
- 5 18 Schuit, F. C., Huypens, P., Heimberg, H. and Pipeleers, D. G. (2001) *Diabetes* **50**, 1-11
- 19 Levin, B. E. (2001) *International Journal of Obesity* **25**
- 20 Alvarez, E., Roncero, I., Chowen, J. A., Thorens, B. and Blazquez, E. (1996) *Journal of Neurochemistry* **66**, 920-7
- 10 21 Mobbs, C. V., Kow, L. M. and Yang, X. J. (2001) *American Journal of Physiology - Endocrinology & Metabolism* **281**, E649-54
- 22 Levin, B. E., Dunn-Meynell, A. A. and Routh, V. H. (1999) *American Journal of Physiology* **276**, R1223-31
- 23 Spanswick, D., Smith, M. A., Groppi, V. E., Logan, S. D. and Ashford, M. L. (1997)
- 15 *Nature* **390**, 521-5
- 24 Spanswick, D., Smith, M. A., Mirshamsi, S., Routh, V. H. and Ashford, M. L. (2000) *Nature Neuroscience* **3**, 757-8
- 25 Levin, B. E. and Dunn-Meynell, A. A. (1997) *Brain Research* **776**, 146-53
- 26 Levin, B. E., Govek, E. K. and Dunn-Meynell, A. A. (1998) *Brain Research* **808**, 317-
- 20 9
- 27 Levin, B. E., Brown, K. L. and Dunn-Meynell, A. A. (1996) *Brain Research* **739**, 293-300
- 28 Rowe, I. C., Boden, P. R. and Ashford, M. L. (1996) *Journal of Physiology* **497**, 365-77
- 25 29 Fujimoto, K., Sakata, T., Arase, K., Kurata, K., Okabe, Y. and Shiraishi, T. (1985) *Life Sciences* **37**, 2475-82
- 30 Kurata, K., Fujimoto, K. and Sakata, T. (1989) *Metabolism: Clinical & Experimental* **38**, 46-51
- 31 Kurata, K., Fujimoto, K., Sakata, T., Etou, H. and Fukagawa, K. (1986) *Physiology & Behavior* **37**, 615-20

- 34 -

Claims

1. A compound of formula (I):



(I)

5 wherein:

Ring A is pyridin-2-yl or thiazol-2-yl; wherein said pyridin-2-yl or thiazol-2-yl may be optionally substituted on carbon by one or more groups selected from R^4 ;

One of R^1 and R^2 is hydrogen and the other is hydrogen or C_{1-4} alkyl; wherein R^1 and R^2 may be substituted on carbon by one or more groups selected from R^5 ;

10 R^3 is selected from C_{1-4} alkyl, C_{1-4} alkoxy, carbocyclyl, heterocyclyl, carbocycloxy and heterocycloxy; wherein R^3 may be independently optionally substituted on carbon by one or more groups selected from R^6 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by C_{1-4} alkyl;

R^4 is selected from halo, carboxy and C_{1-4} alkyl;

15 R^5 and R^6 are independently selected from halo, C_{1-4} alkyl, C_{1-4} alkoxy, N -(C_{1-4} alkyl)amino, N,N -(C_{1-4} alkyl)₂amino, carbocyclyl, heterocyclyl, carbocycloxy, heterocycloxy and carbocyclidenyl; wherein R^5 and R^6 may be independently optionally substituted on carbon by one or more R^7 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally

20 substituted by C_{1-4} alkyl;

R^7 is selected from halo, carboxy, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and N -methyl- N -ethylamino;

or a salt, solvate or pro-drug thereof.

25 2. A compound according to Claim 1 wherein Ring A is unsubstituted or is substituted by carboxy.


3. A compounds according to any one of the preceding claims wherein one of R^1 and R^2 is hydrogen and the other is hydrogen or C_{1-4} alkyl.

- 35 -

4. A compound according to any one of the preceding claims wherein R^3 is selected from C_{1-4} alkoxy; wherein R^3 may be independently optionally substituted on carbon by one or more groups selected from R^6 .
- 5
5. A compound according to any one of the preceding claims wherein R^3 is selected from 2-fluorobenzyloxy, 5-methylisoxazol-3-ylmethoxy and 2-thien-3-ylethoxy
6. A compound according to Claim 1 selected from:
- 10 2-methyl-4-isobutoxy-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;
2-methyl-4-(2-fluorophenylmethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;
2-methyl-4-isobutoxy-6-[N-(5-carboxythiazol-2-yl)carbamoyl]benzofuran;
2-methyl-4-(5-methylisoxazol-3-ylmethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;
- 15 4-(2-fluorophenylmethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;
4-(5-methylisoxazol-3-ylmethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;
2-methyl-4-(thien-2-ylethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;
- 20 and
2-methyl-4-isobutoxy-6-[N-(thiazol-2-yl)carbamoyl]benzofuran;
or a salt, solvate or pro-drug thereof.
7. A pharmaceutical composition comprising a compound according to any one of Claims 1 to 6, or a salt, pro-drug or solvate thereof, together with a pharmaceutically acceptable diluent or carrier.
- 25
8. A compound according to any one of Claims 1 to 6 for use in the preparation of a medicament for treatment of a disease mediated through GLK.
- 30
9. A process for preparing a compound of formula (I), as defined in Claim 1, or a salt, solvate or pro-drug thereof which process (wherein variable groups are, unless otherwise specified, as defined in Claim 1) comprises:


- 36 -

Process 1): reacting an acid of formula (II):




(II)

or an activated derivative thereof; with a compound of formula (III); or



(III)

Process 2) for compounds of formula (I) wherein R⁴ is carboxy; deprotecting a compound of formula (III):



(III)

wherein R^xC(O)O- is an ester group;

and thereafter if necessary or desirable:

- i) converting a compound of the formula (I) into another compound of the formula (I); and/or
- ii) removing any protecting groups; and/or
- iii) forming a salt, solvate or pro-drug thereof.

10. A compound of formula (III) as defined in Claim 9.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 03/04919

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D413/12 C07D419/12 C07D413/14 C07D419/14 C07D307/80
A61P3/04 A61P3/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

PAJ, WPI Data, EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01 44216 A (HOFFMANN LA ROCHE) 21 June 2001 (2001-06-21) cited in the application page 21, line 11 -page 21, line 16; examples 1-25 -----	1-9

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

11 February 2004

Date of mailing of the international search report

26/02/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Schmid, A

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 03/04919

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 10
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.2

Claims Nos.: 10

Claim 10 refers back to a formula (III) as defined in claim 9. However, looking at claim 9, it becomes evident that there are 2 structure with the formula (III). Accordingly it is not clear which of the 2 structures is meant, so that no search can be done.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 03/04919

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0144216	A	21-06-2001	AU 2365201 A	25-06-2001
			CA 2392903 A1	21-06-2001
			CN 1411453 T	16-04-2003
			CZ 20022412 A3	16-10-2002
			WO 0144216 A1	21-06-2001
			EP 1242397 A1	25-09-2002
			HU 0203753 A2	28-03-2003
			JP 2003516980 T	20-05-2003
			NO 20022863 A	14-06-2002
			US 6353111 B1	05-03-2002